SLRN: Acelyrin, Inc. Cash on Hand per Share

acelyrin.com - graphic logo of issuer SLRN

The biopharmaceutical sector is constrained by supply chain vulnerabilities and regulatory barriers. The price action of high-liquidity assets per share demonstrates the current resilience of Acelyrin, Inc. (SLRN), where the 4.08 metric serves as the target level. Acelyrin, Inc. (SLRN) is currently optimizing expenses and scaling back its research program to ensure survival. However, the development of unique immunological drugs opens prospects for monopoly pricing power over future therapies.

ACELYRIN, Inc. (SLRN) - Cash per Share from 02/21/2024 to 05/31/2025

Analytical breakdowns for ACELYRIN (SLRN)

- stock quotes and analyst forecast:
- market capitalization information:
- cash availability and cash flow indicators:
Summary company analysis:Acelyrin, Inc.
Product sample of acelyrin.com

Acelyrin, Inc. (SLRN) develops highly scalable drugs to combat immune pathologies, aiming for a global monopoly through patent protection. The dynamics of highly liquid assets per share reflect the volume of available capital allocated to a single common share. This metric serves as an express screening tool to assess the dollar fundamental and solvency of the issuer. A high cash reserve minimizes default risk but may signal low resource efficiency. Analysis of this chart allows for the determination of the balance between financial stability and potential investment returns.

Analysis of competing companies

Cash on Hand per Share Haleon Corp HLN|Cash per Single Share KVUE (Kenvue Health)|Verona Pharma plc - Cash Funds per Single Share|Jyong Biotech - Cash per Single Share|LGND: Cash Funds per Single Share|AMRX: Cash per Single Share|Cash on Hand per Share Perrigo Company plc|ALVO: Cash per Share|Liquidia (LQDA) - Cash per Share|Cash Funds per Share Galapagos N.V.|Cash per Single Share ANI Pharmaceuticals, Inc. (ANIP)|Cash per Share MNKD|AMPH (Amphastar Corp) - Amount of Cash per Share|Cash Funds per Share pacira.com PCRX|SPRY - Cash per Single Share|Theravance Biopharma, Inc. - Cash per Share|Amount of Cash per Share AQST (Aquestive Therapeutics, Inc.)|SCPH: Cash per Share|Tectonic Therapeutic Inc. - Amount of Cash per Share|TNXP (Tonix Pharma) - Cash per Share|SXTC: Amount of Cash per Share|Cash per Share EPRX|BHST - Cash on Hand per Share|eXoZymes - Cash per Single Share|Cash per Share oramed.com ORMP|ENTX - Cash Funds per Share|Cash Funds Calculated per Share MindWalk Holdings HYFT|ABVC: Cash per Share|Cash per Single Share Cumberland Pharmaceuticals Inc.|Cash Funds per Share Quantum BioPharma Limited|FGEN: Amount of Cash per Share|Cash per Share TELO|Rani Therapeutics Holdings, Inc. - Cash Funds per Single Share|Cash Funds per Share Synergy CHC Corp. SNYR|Amount of Cash per Share RLYB|LEXX: Cash per Single Share|Amount of Cash per Share PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Cash Funds per Share|Cash per Single Share Aptorum|Cash per Single Share LYRA|Impact BioMedical Inc - Cash Money per Share|Cash per Share TNFA|YCBD - Cash on Hand per Share|PainReform Ltd. - Cash per Single Share|CYTO (Auris Medical) - Cash Money per Share|LIPO - Cash Funds per Share|Amount of Cash per Share OPTN (OptiNose)|PIRS: Cash per Share|Procaps Group S.A. (PROC) - Cash per Share|PTPI (Petros Pharma) - Cash per Share|QLI: Amount of Cash per Share|Cash per Single Share TFFP (TFF Pharmaceuticals, Inc.)